Qurient Data Shows Q901 Enhances TOP1 Inhibitor ADCs
Qurient published peer-reviewed data showing its CDK7 inhibitor Q901 enhances the antitumor activity of TOP1 inhibitor-based antibody-drug conjugates (ADCs). The findings support the development of combination and dual-payload ADCs.